Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to si...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
The innovative 'digiverse' that's propelling transformative decentralised clinical trials
Dr. Isaac R. Rodriguez-Chavez offers his insights on the use of innovative digital health technologies and digital ecosystems to support decentralised clinical trials.
International Clinical Trials, May 2022, pages 54-57. Samedan Ltd
-
Identifying integrated digital platforms designed for a decentralised future
Matt Harrington, VP of Connected Health Technology Solutions, explores how the use of digital platforms and associated services can contribute to more adaptable, accessible and efficient clinical trials.
-
Putting patients at the heart of clinical trials
Scott Palmese, Senior Director, Accellacare Site Network, shares his insights on optimising the patient experience within clinical trials, and the ramifications of the COVID-19 pandemic (page 14).
-
JPM 2022: Decentralised trials, broader service offerings and novel drugs key trends in the CRO space
In this snapshot from the J.P. Morgan Healthcare Conference, Steve Cutler comments on ICON’s success in decentralised trials and therapeutic technologies such as mRNA and checkpoint inhibitors.
-
In-Home Services: A patient-centric approach to improving recruitment and retention in clinical trials
Advances in wearables, telemedicine and remote monitoring technology along with the convenience of in-home visits were bound to make decentralised and hybrid clinical trials standard with enough time. However, the COVID-19 pandemic accelerated their adoption and now, even with the hope that the pandemic will soon be behind us, hybrid and decentralised models are poised to become viable solutions in clinical trial design because of their inherent agility, inclusivity and most importantly, patient centricity.
-
Capture, curate, consume: The three Cs of managing data in decentralised and hybrid clinical trials
Emily Mitchell, Executive Director, Decentralised Clinical Trials Operations and Christina Dinger, Director, Decentralised Clinical Trials Operations, run through some of the most important elements of collating and organising data during clinical trials.
This article was taken from Pharmafocus December 2021, pages 16-17. Samedan Ltd.
-
ICON expands Accellacare Site Network
An article reporting on ICON's recent announcement that its Accellacare Site Network has entered new partnerships with six research sites across four countries, expanding its global footprint and capabilities.
-
-
Operationalising decentralised clinical trials
In this article, our experts discuss the challenges and change management approaches that ICON faced during the COVID-19 pandemic, and how we overcame them through the use of decentralised and hybrid clinical trials (see page 14).
-
CROs: Yesterday, today, and tomorrow
ICON's Kent Thoelke discusses today’s key trends for CROs, including the increasing adoption of decentralised clinical trials (DCTs) and the growing use of remote monitoring to collect data.
